{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:42:01Z","timestamp":1793032921510,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04384-1","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:46:35Z","timestamp":1776257195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations"],"prefix":"10.1007","volume":"75","author":[{"given":"Mahsa","family":"Fatahichegeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Ansarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"9","key":"4384_CR1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S1470-2045(19)30339-0","volume":"20","author":"LM Force","year":"2019","unstructured":"Force LM, Abdollahpour I, Advani SM, Agius D, Ahmadian E, Alahdab F, Alam T, Alebel A, Alipour V, Allen CA (2019) The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncol 20(9):1211\u20131225","journal-title":"Lancet Oncol"},{"issue":"10","key":"4384_CR2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1200\/JCO.23.00458","volume":"42","author":"L Moreno","year":"2024","unstructured":"Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V, Zwaan CM, Nysom K, Gerber N, Castellano A (2024) Bevacizumab, irinotecan, or topotecan added to temozolomide for children with relapsed and refractory neuroblastoma: results of the ITCC-SIOPEN BEACON-neuroblastoma trial. J Clin Oncol 42(10):1135\u20131145","journal-title":"J Clin Oncol"},{"issue":"7","key":"4384_CR3","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41416-025-03118-x","volume":"133","author":"A Rubio-San-Sim\u00f3n","year":"2025","unstructured":"Rubio-San-Sim\u00f3n A, Wilson W, Sironi G, Le Deley MC, Palmerini E, Gaspar N, Meazza C (2025) Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review: Clinical Study. Br j cancer 133(7):1020\u20131028","journal-title":"Br j cancer"},{"issue":"12","key":"4384_CR4","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1001\/jamaoncol.2023.4437","volume":"9","author":"A Peyrl","year":"2023","unstructured":"Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T (2023) Sustained survival benefit in recurrent medulloblastoma by a metronomic antiangiogenic regimen: a nonrandomized controlled trial. JAMA Oncol 9(12):1688\u20131695","journal-title":"JAMA Oncol"},{"issue":"1","key":"4384_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2024","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG (2024) Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 392(1):11","journal-title":"N Engl J Med"},{"issue":"9","key":"4384_CR6","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, De Moerloose B, Qayed M (2023) Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol 41(9):1664\u20131669","journal-title":"J Clin Oncol"},{"issue":"5","key":"4384_CR7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.cell.2024.12.014","volume":"188","author":"Q Chen","year":"2025","unstructured":"Chen Q, Zhao B, Tan Z, Hedberg G, Wang J, Gonzalez L, Brodin P (2025) Systems-level immunomonitoring in children with solid tumors to enable precision medicine. Cell 188(5):1425\u20131440","journal-title":"Cell"},{"issue":"1","key":"4384_CR8","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1038\/s41467-024-49944-0","volume":"15","author":"SJ Forrest","year":"2024","unstructured":"Forrest SJ, Gupta H, Ward A, Li YY, Doan D, Al-Ibraheemi A, Alexandrescu S, Bandopadhayay P, Shusterman S, Mullen EA (2024) Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun 15(1):5837","journal-title":"Nat Commun"},{"issue":"1","key":"4384_CR9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","volume":"18","author":"S Sun","year":"2025","unstructured":"Sun S, Liu L, Zhang J, Sun L, Shu W, Yang Z, Yao H, Zhang Z (2025) The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives. J Hematol Oncol 18(1):84","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4384_CR10","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1038\/s41467-024-46835-2","volume":"15","author":"CF Ramirez","year":"2024","unstructured":"Ramirez CF, Taranto D, Ando-Kuri M, de Groot MH, Tsouri E, Huang Z, de Groot D, Kluin RJ, Kloosterman DJ, Verheij J (2024) Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma. Nat Commun 15(1):2581","journal-title":"Nat Commun"},{"issue":"9","key":"4384_CR11","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.4049\/jimmunol.1301966","volume":"191","author":"AM Griesinger","year":"2013","unstructured":"Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH, Foreman NK (2013) Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol 191(9):4880\u20134888","journal-title":"J Immunol"},{"issue":"4","key":"4384_CR12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/cancers13040817","volume":"13","author":"M Ishfaq","year":"2021","unstructured":"Ishfaq M, Pham T, Beaman C, Tamayo P, Yu AL, Joshi S (2021) BTK inhibition reverses MDSC-mediated immunosuppression and enhances response to anti-PDL1 therapy in neuroblastoma. Cancers 13(4):817","journal-title":"Cancers"},{"issue":"23","key":"4384_CR13","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/0008-5472.CAN-21-1033","volume":"81","author":"SA Byron","year":"2021","unstructured":"Byron SA, Hendricks WP, Nagulapally AB, Kraveka JM, Ferguson WS, Brown VI, Eslin DE, Mitchell D, Cornelius A, Roberts W (2021) Genomic and transcriptomic analysis of relapsed and refractory childhood solid tumors reveals a diverse molecular landscape and mechanisms of immune evasion. Cancer Res 81(23):5818\u20135832","journal-title":"Cancer Res"},{"key":"4384_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2024.100675","author":"IA van Belzen","year":"2024","unstructured":"van Belzen IA, van Tuil M, Badloe S, Janse A, Verwiel ET, Santoso M, de Vos S, Baker-Hernandez J, Kerstens HH, Solleveld-Westerink N (2024) Complex structural variation is prevalent and highly pathogenic in pediatric solid tumors. Cell genomics. https:\/\/doi.org\/10.1016\/j.xgen.2024.100675","journal-title":"Cell genomics"},{"issue":"6","key":"4384_CR15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41568-024-00684-9","volume":"24","author":"X Chen","year":"2024","unstructured":"Chen X, Yang W, Roberts CW, Zhang J (2024) Developmental origins shape the paediatric cancer genome. Nat Rev Cancer 24(6):382\u2013398","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4384_CR16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jnci\/djy157","volume":"111","author":"WL Hwang","year":"2019","unstructured":"Hwang WL, Wolfson RL, Niemierko A, Marcus KJ, DuBois SG, Haas-Kogan D (2019) Clinical impact of tumor mutational burden in neuroblastoma. JNCI: J Natl Cancer Inst 111(7):695\u2013699","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"8","key":"4384_CR17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/ng.3333","volume":"47","author":"TF Eleveld","year":"2015","unstructured":"Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M (2015) Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet 47(8):864\u2013871","journal-title":"Nat Genet"},{"issue":"1","key":"4384_CR18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78370-7","volume":"10","author":"S Fransson","year":"2020","unstructured":"Fransson S, Martinez-Monleon A, Johansson M, Sj\u00f6berg R-M, Bj\u00f6rklund C, Ljungman G, Ek T, Kogner P, Martinsson T (2020) Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance. Sci Rep 10(1):22432","journal-title":"Sci Rep"},{"issue":"16","key":"4384_CR19","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13164765","volume":"13","author":"NV Persaud","year":"2024","unstructured":"Persaud NV, Park JA, Cheung NKV (2024) High-risk neuroblastoma challenges and opportunities for antibody-based cellular immunotherapy. J Clin Med 13(16):4765","journal-title":"J Clin Med"},{"key":"4384_CR20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1394284","volume":"15","author":"S Orrapin","year":"2024","unstructured":"Orrapin S, Moonmuang S, Udomruk S, Yongpitakwattana P, Pruksakorn D, Chaiyawat P (2024) Unlocking the tumor-immune microenvironment in osteosarcoma: insights into the immune landscape and mechanisms. Front Immunol 15:1394284","journal-title":"Front Immunol"},{"issue":"1","key":"4384_CR21","volume":"13","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Wang J, Sun M, Zuo D, Wang H, Shen J, Jiang W, Mu H, Ma X, Yin F (2022) Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. Nat Commun 13(1):7207","journal-title":"Nat Commun"},{"issue":"1","key":"4384_CR22","volume":"11","author":"C-C Wu","year":"2020","unstructured":"Wu C-C, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang W-L, Ju Z (2020) Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008","journal-title":"Nat Commun"},{"issue":"11","key":"4384_CR23","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-14-0622","volume":"4","author":"F Tirode","year":"2014","unstructured":"Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, Zhang Z, Lapouble E, Grosset\u00eate-Lalami S, Rusch M (2014) Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 4(11):1342\u20131353","journal-title":"Cancer Discov"},{"issue":"10","key":"4384_CR24","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1158\/2767-9764.CRC-23-0027","volume":"3","author":"LL Visser","year":"2023","unstructured":"Visser LL, Bleijs M, Margaritis T, van de Wetering M, Holstege FC, Clevers H (2023) Ewing sarcoma single-cell transcriptome analysis reveals functionally impaired antigen-presenting cells. Cancer Res Commun 3(10):2158\u20132169","journal-title":"Cancer Res Commun"},{"issue":"1","key":"4384_CR25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41698-022-00307-2","volume":"6","author":"DS Shulman","year":"2022","unstructured":"Shulman DS, Whittle SB, Surdez D, Bailey KM, de \u00c1lava E, Yustein JT, Shlien A, Hayashi M, Bishop AJ, Crompton BD (2022) An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ precis oncol. 6(1):65","journal-title":"NPJ precis oncol."},{"issue":"6405","key":"4384_CR26","doi-asserted-by":"crossref","DOI":"10.1126\/science.aam8419","volume":"361","author":"ND Anderson","year":"2018","unstructured":"Anderson ND, de Borja R, Young MD, Fuligni F, Rosic A, Roberts ND, Hajjar S, Layeghifard M, Novokmet A, Kowalski PE (2018) Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science 361(6405):eaam8419","journal-title":"Science"},{"issue":"11","key":"4384_CR27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nbt.4239","volume":"36","author":"AC Smart","year":"2018","unstructured":"Smart AC, Margolis CA, Pimentel H, He MX, Miao D, Adeegbe D, Fugmann T, Wong K-K, Van Allen EM (2018) Intron retention is a source of neoepitopes in cancer. Nat biotechnol. 36(11):1056\u20131058","journal-title":"Nat biotechnol."},{"issue":"9","key":"4384_CR28","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3390\/children12091249","volume":"12","author":"OA El Meligy","year":"2025","unstructured":"El Meligy OA, Elemam NM, Hassan WA, Talaat IM (2025) Tumor-immune interactions in pediatric oral rhabdomyosarcoma: a narrative review on immuno-oncology and emerging therapies. Children. 12(9):1249","journal-title":"Children."},{"issue":"2","key":"4384_CR29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","volume":"4","author":"JF Shern","year":"2014","unstructured":"Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK (2014) Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer discov. 4(2):216\u2013231","journal-title":"Cancer discov."},{"issue":"7_Supplement","key":"4384_CR30","doi-asserted-by":"crossref","first-page":"6736","DOI":"10.1158\/1538-7445.AM2023-6736","volume":"83","author":"D Milewski","year":"2023","unstructured":"Milewski D, Tian M, Kim Y, Wei J, Khan J (2023) Suppression of antigen presentation is a hallmark of pediatric rhabdomyosarcoma. Cancer Res 83(7_Supplement):6736\u20136736","journal-title":"Cancer Res"},{"issue":"3","key":"4384_CR31","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30139","volume":"70","author":"R Parisi","year":"2023","unstructured":"Parisi R, Patel RR, Rood G, Bowden A, Turco G, Korones DN, Andolina JR, Comito M, Barth M, Weintraub L (2023) Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients. Pediatr Blood Cancer. 70(3):e30139","journal-title":"Pediatr Blood Cancer."},{"issue":"5","key":"4384_CR32","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s43018-023-00706-9","volume":"5","author":"A Upadhye","year":"2024","unstructured":"Upadhye A, Meza Landeros KE, Ram\u00edrez-Su\u00e1stegui C, Schmiedel BJ, Woo E, Chee SJ, Malicki D, Coufal NG, Gonda D, Levy ML (2024) Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties. Nat cancer. 5(5):791\u2013807","journal-title":"Nat cancer."},{"issue":"9","key":"4384_CR33","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jcyt.2019.06.009","volume":"21","author":"F Blaeschke","year":"2019","unstructured":"Blaeschke F, Paul MC, Schuhmann MU, Rabsteyn A, Schroeder C, Casadei N, Matthes J, Mohr C, Lotfi R, Wagner B (2019) Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy. Cytotherapy. 21(9):973\u2013986","journal-title":"Cytotherapy."},{"issue":"1","key":"4384_CR34","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1038\/s41467-021-26936-y","volume":"12","author":"S Rivero-Hinojosa","year":"2021","unstructured":"Rivero-Hinojosa S, Grant M, Panigrahi A, Zhang H, Caisova V, Bollard CM, Rood BR (2021) Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors. Nat commun. 12(1):6689","journal-title":"Nat commun."},{"issue":"23","key":"4384_CR35","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-23-0411","volume":"29","author":"A Das","year":"2023","unstructured":"Das A, Tabori U, Sambira Nahum LC, Collins NB, Deyell R, Dvir R, Faure-Conter C, Hassall TE, Minturn JE, Edwards M (2023) Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch repair deficiency. Clin Cancer Res. 29(23):4770\u20134783","journal-title":"Clin Cancer Res."},{"issue":"19","key":"4384_CR36","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet E, Larouche V, Campbell BB, Merico D, De Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J clin oncol. 34(19):2206\u20132211","journal-title":"J clin oncol."},{"issue":"12","key":"4384_CR37","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1634\/theoncologist.2018-0163","volume":"23","author":"M AlHarbi","year":"2018","unstructured":"AlHarbi M, Ali Mobark N, AlMubarak L, Aljelaify R, AlSaeed M, Almutairi A, Alqubaishi F, Hussain ME, Balbaid AAO, Said Marie A (2018) Durable response to nivolumab in a pediatric patient with refractory glioblastoma and constitutional biallelic mismatch repair deficiency. oncologist. 23(12):1401\u20131406","journal-title":"oncologist."},{"issue":"1","key":"4384_CR38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41591-021-01581-6","volume":"28","author":"A Das","year":"2022","unstructured":"Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone SC, Alsafwani N, Liu ZA, Karsaneh OAA, Soleimani S (2022) Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat med. 28(1):125\u2013135","journal-title":"Nat med."},{"issue":"6","key":"4384_CR39","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.7150\/thno.105276","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang H, Zhou F, Qin W, Yang Y, Li X, Liu R (2025) Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies. Theranostics. 15(6):2159","journal-title":"Theranostics."},{"issue":"5","key":"4384_CR40","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41588-025-02158-6","volume":"57","author":"W Yu","year":"2025","unstructured":"Yu W, Biyik-Sit R, Uzun Y, Chen C-H, Thadi A, Sussman JH, Pang M, Wu C-Y, Grossmann LD, Gao P (2025) Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring. Nat Genet. 57(5):1142\u20131154","journal-title":"Nat Genet."},{"issue":"1","key":"4384_CR41","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","volume":"23","author":"S Yu","year":"2024","unstructured":"Yu S, Yao X (2024) Advances on immunotherapy for osteosarcoma. Mol cancer. 23(1):192","journal-title":"Mol cancer."},{"issue":"4","key":"4384_CR42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s43018-024-00726-z","volume":"5","author":"CL Roland","year":"2024","unstructured":"Roland CL, Nassif Haddad EF, Keung EZ, Wang W-L, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA (2024) A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity\/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 5(4):625\u2013641","journal-title":"Nat Cancer."},{"issue":"7791","key":"4384_CR43","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, De Reyni\u00e9s A, Keung EZ, Chen TW-W, Sun C-M, Calderaro J, Jeng Y-M, Hsiao L-P, Lacroix L, Bougo\u00fcin A (2020) B cells are associated with survival and immunotherapy response in sarcoma. Nature 577(7791):556\u2013560","journal-title":"Nature"},{"issue":"1","key":"4384_CR44","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1038\/s41467-024-50527-2","volume":"15","author":"SG Danielli","year":"2024","unstructured":"Danielli SG, Wei Y, Dyer MA, Stewart E, Sheppard H, Wachtel M, Sch\u00e4fer BW, Patel AG, Langenau DM (2024) Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma. Nat commun. 15(1):6307","journal-title":"Nat commun."},{"issue":"237","key":"4384_CR45","doi-asserted-by":"crossref","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","volume":"6","author":"SL Highfill","year":"2014","unstructured":"Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, Kaplan RN, Mackall CL (2014) Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci transl med 6(237):237ra67-237ra67","journal-title":"Sci transl med"},{"issue":"1","key":"4384_CR46","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41467-025-56619-x","volume":"16","author":"J Mora","year":"2025","unstructured":"Mora J, Chan GC, Morgenstern DA, Amoroso L, Nysom K, Faber J, Wingerter A, Bear MK, Rubio-San-Simon A, de Las Heras BM (2025) The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial. Nat Commun. 16(1):1636","journal-title":"Nat Commun."},{"issue":"8","key":"4384_CR47","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","volume":"27","author":"AL Yu","year":"2021","unstructured":"Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC (2021) Long-term follow-up of a phase III study of ch14. 18 (dinutuximab)+ cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clin Cancer Res 27(8):2179\u20132189","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4384_CR48","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/pharmaceutics15020648","volume":"15","author":"L Galassi","year":"2023","unstructured":"Galassi L, Rossi M, Lodeserto P, Lenzi M, Borsetti F, Voltattorni M, Farruggia G, Blasi P, Orienti I (2023) Naxitamab activity in neuroblastoma cells is enhanced by nanofenretinide and nanospermidine. Pharmaceutics. 15(2):648","journal-title":"Pharmaceutics."},{"issue":"8","key":"4384_CR49","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/ijc.34815","volume":"154","author":"J Mora","year":"2024","unstructured":"Mora J, Modak S, Kinsey J, Ragsdale CE, Lazarus HM (2024) GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma. Int j cancer. 154(8):1340\u20131364","journal-title":"Int j cancer."},{"issue":"5","key":"4384_CR50","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30217","volume":"70","author":"K Nysom","year":"2023","unstructured":"Nysom K, Morad AG, Rafael MS, Zier J, Marachelian A, Watt T, Morgenstern DA (2023) Pain mitigation and management strategies for anti\u2010GD2 infusions: an expert consensus. Pediatr Blood Cancer 70(5):e30217","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"4384_CR51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jaapos.2014.11.005","volume":"19","author":"CT Brian","year":"2015","unstructured":"Brian CT, Navid F, Billups CA, O\u2019Donnell T, Hoehn ME (2015) Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14. 18K322A. J Am Assoc Pediatr Ophthalmol Strabismus 19(2):112\u2013115","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"issue":"11","key":"4384_CR52","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/s41416-023-02457-x","volume":"129","author":"HN Lode","year":"2023","unstructured":"Lode HN, Ehlert K, Huber S, Troschke-Meurer S, Siebert N, Zumpe M, Loibner H, Ladenstein R (2023) Long-term, continuous infusion of single-agent dinutuximab beta for relapsed\/refractory neuroblastoma: an open-label, single-arm, Phase 2 study. Br J Cancer 129(11):1780\u20131786","journal-title":"Br J Cancer"},{"issue":"1","key":"4384_CR53","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, Hou P, Cui Q, Xu Z, Wang W (2025) Antibody\u2013drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol 18(1):51","journal-title":"J Hematol Oncol"},{"key":"4384_CR54","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c02941","author":"H Tian","year":"2026","unstructured":"Tian H, Pan W, Shi H, Shao X, Sun J, Liang J, Chen B, Cheng B, Liu K, Yao G (2026) Coibamide analogue as a novel-class payload for antibody-drug conjugate. J Med Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02941","journal-title":"J Med Chem"},{"key":"4384_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08397-z","author":"G Bianchi","year":"2026","unstructured":"Bianchi G, Pastorino F, Rolandi G, Ciampi E, Segalerba D, De Giovanni B, Cafferata B, Balbi M, Ravera S, Vellone VG (2026) The investigational anti-B7-H3 antibody-drug conjugate vobramitamab duocarmazine exerts anti-tumor activity in vitro and in vivo in pediatric sarcoma preclinical models. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-025-08397-z","journal-title":"Cell Death Dis"},{"issue":"9","key":"4384_CR56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007174","volume":"11","author":"C Brignole","year":"2023","unstructured":"Brignole C, Calarco E, Bensa V, Giusto E, Perri P, Ciampi E, Corrias MV, Astigiano S, Cilli M, Loo D (2023) Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma. J Immunother Cancer 11(9):e007174","journal-title":"J Immunother Cancer"},{"key":"4384_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2","author":"Y Ma","year":"2025","unstructured":"Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X, Fan Y, Fu S, Wu L, Zheng Y (2025) A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial. Nat med. https:\/\/doi.org\/10.1038\/s41591-025-03600-2","journal-title":"Nat med"},{"key":"4384_CR58","doi-asserted-by":"crossref","unstructured":"Kurmasheva R, Mosse YP, Del Pozo V, Earley EJ, Erickson SW, Groff D, Kolb EA, Krytska K, Smith MA, Tsang M. Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC). Wolters Kluwer Health; 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.10037"},{"issue":"7_Supplement","key":"4384_CR59","doi-asserted-by":"crossref","first-page":"ND08","DOI":"10.1158\/1538-7445.AM2024-ND08","volume":"84","author":"C Amendt","year":"2024","unstructured":"Amendt C, Knuehl C, Crandall T, Sloot W, Toister-Achituv M, Sweeney-Lasch S, Pereira JN, Dotterweich J, Boehm HH, Ma J (2024) Abstract ND08: M3554, a novel anti-GD2 antibody drug conjugate. Cancer Res 84(7_Supplement):ND08\u2013ND08","journal-title":"Cancer Res"},{"issue":"2","key":"4384_CR60","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/abt\/tbae005","volume":"7","author":"X Ma","year":"2024","unstructured":"Ma X, Wang M, Ying T, Wu Y (2024) Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate. Antibody Ther 7(2):114\u2013122","journal-title":"Antibody Ther"},{"issue":"12","key":"4384_CR61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004704","volume":"10","author":"G Pascual-Pasto","year":"2022","unstructured":"Pascual-Pasto G, McIntyre B, Shraim R, Buongervino SN, Erbe AK, Zhelev DV, Sadirova S, Giudice AM, Martinez D, Garcia-Gerique L (2022) GPC2 antibody\u2013drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies. J Immunother Cancer 10(12):e004704","journal-title":"J Immunother Cancer"},{"issue":"45","key":"4384_CR62","volume":"122","author":"J Wang","year":"2025","unstructured":"Wang J, Huang X, Shi Q, Swingle KL, Hamilton AG, Gong N, Mitchell MJ (2025) Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy. Proc Natl Acad Sci U S A 122(45):e2409564122","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"4384_CR63","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","volume":"392","author":"S Gupta","year":"2025","unstructured":"Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L (2025) Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N Engl J Med 392(9):875\u2013891","journal-title":"N Engl J Med"},{"issue":"3","key":"4384_CR64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008744","volume":"12","author":"M Yankelevich","year":"2024","unstructured":"Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk D, Schienshang A, Whitaker S, Rea K (2024) Targeting refractory\/recurrent neuroblastoma and osteosarcoma with anti-CD3\u00d7 anti-GD2 bispecific antibody armed T cells. J Immunother Cancer 12(3):e008744","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4384_CR65","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-51337-2","volume":"15","author":"G Pascual-Pasto","year":"2024","unstructured":"Pascual-Pasto G, McIntyre B, Hines MG, Giudice AM, Garcia-Gerique L, Hoffmann J, Mishra P, Matlaga S, Lombardi S, Shraim R (2024) CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma. Nat Commun 15(1):7141","journal-title":"Nat Commun"},{"issue":"8","key":"4384_CR66","doi-asserted-by":"crossref","first-page":"11937","DOI":"10.1021\/acsami.5c00633","volume":"17","author":"J Parra-Nieto","year":"2025","unstructured":"Parra-Nieto J, Hidalgo L, M\u00e1rquez-Cantudo M, Garc\u00eda-Castro J, Megias D, Ramirez M, Baeza A (2025) Liposomal-based nanoarchitectonics as bispecific T Cell engagers in neuroblastoma therapy. ACS Appl Mater Interfaces 17(8):11937\u201311945","journal-title":"ACS Appl Mater Interfaces"},{"issue":"8","key":"4384_CR67","volume":"13","author":"AK Park","year":"2025","unstructured":"Park AK, Monroy I, Ren Y, Lu C, Chaurasiya S, Valencia H, Lent-Koop J, Cook C, Kang S, Lopez L (2025) Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors. J Immunother Cancer 13(8):e011051","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4384_CR68","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","volume":"31","author":"F Locatelli","year":"2025","unstructured":"Locatelli F, Pagliara D, De Ioris MA, Becilli M, Del Baldo G, Serra A, del Bufalo F (2025) GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial. Nat med 31(11):3689\u20133699","journal-title":"Nat med"},{"key":"4384_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03513-0","author":"C-H Li","year":"2025","unstructured":"Li C-H, Sharma S, Heczey AA, Woods ML, Steffin DH, Louis CU, Grilley BJ, Thakkar SG, Wu M, Wang T (2025) Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03513-0","journal-title":"Nat Med"},{"issue":"35","key":"4384_CR70","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1200\/JCO.23.02229","volume":"42","author":"N Pinto","year":"2024","unstructured":"Pinto N, Albert CM, Taylor MR, Ullom HB, Wilson AL, Huang W, Wendler J, Pattabhi S, Seidel K, Brown C (2024) STRIvE-02: a first-in-human phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors. J Clin Oncol 42(35):4163\u20134172","journal-title":"J Clin Oncol"},{"key":"4384_CR71","volume":"3","author":"R Epperly","year":"2024","unstructured":"Epperly R, Gottschalk S, DeRenzo C (2024) CAR T cells redirected to B7-H3 for pediatric solid tumors: current status and future perspectives. EJC Paediatr Oncol 3:100160","journal-title":"EJC Paediatr Oncol"},{"issue":"3","key":"4384_CR72","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza NA, Ronsley R, Choe M, Seidel K, Huang W, Rawlings-Rhea SD, Beam M, Steinmetzer L, Wilson AL, Brown C (2025) Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med 31(3):861\u2013868","journal-title":"Nat Med"},{"issue":"1","key":"4384_CR73","volume":"11","author":"M Sun","year":"2023","unstructured":"Sun M, Cao Y, Okada R, Reyes-Gonz\u00e1lez JM, Stack HG, Qin H, Li N, Seibert C, Kelly MC, Ruppin E (2023) Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma. J Immunother Cancer 11(1):e005881","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4384_CR74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","volume":"40","author":"S Heitzeneder","year":"2022","unstructured":"Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G (2022) GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell 40(1):53-69.e9","journal-title":"Cancer Cell"},{"issue":"9","key":"4384_CR75","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/2326-6066.CIR-24-0975","volume":"13","author":"R Okada","year":"2025","unstructured":"Okada R, Reyes-Gonz\u00e1lez JM, Rodriguez C, Kondo T, Oh J, Sun M, Nguyen R (2025) GPC2-targeted CAR T cells engineered with NFAT-inducible membrane-tethered IL15\/IL21 exhibit enhanced activity against neuroblastoma. Cancer Immunol Res 13(9):1363\u20131373","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"4384_CR76","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","volume":"5","author":"M Hegde","year":"2024","unstructured":"Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, Gad AZ, Janeway KA, Campbell M, Mullikin D (2024) Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer 5(6):880\u2013894","journal-title":"Nat Cancer"},{"issue":"1","key":"4384_CR77","volume":"11","author":"M Hegde","year":"2020","unstructured":"Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C (2020) Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun 11(1):3549","journal-title":"Nat Commun"},{"issue":"S1","key":"4384_CR78","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","volume":"94","author":"S Feins","year":"2019","unstructured":"Feins S, Kong W, Williams EF, Milone MC, Fraietta JA (2019) An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol 94(S1):S3-s9. https:\/\/doi.org\/10.1002\/ajh.25418.","journal-title":"Am J Hematol"},{"issue":"4","key":"4384_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"issue":"8046","key":"4384_CR80","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, Barsan V, Song K-W, Kamens J, Baggott C (2025) Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637(8046):708\u2013715","journal-title":"Nature"},{"issue":"6","key":"4384_CR81","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1433518","volume":"7","author":"C Quintarelli","year":"2018","unstructured":"Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F (2018) Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology 7(6):e1433518","journal-title":"Oncoimmunology"},{"issue":"10","key":"4384_CR82","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41417-024-00823-2","volume":"31","author":"W Xiao","year":"2024","unstructured":"Xiao W, Xu L, Wang J, Yu K, Xu B, Que Y, Zhao J, Pan Q, Gao C, Zhou P (2024) FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma. Cancer Gene Ther 31(10):1571\u20131584","journal-title":"Cancer Gene Ther"},{"key":"4384_CR83","doi-asserted-by":"crossref","unstructured":"Pang Y, Chen L, Sun Q, He N, Lai Z, Wang X, Xie Z, Yang W, Wang W. A new strategy for CAR-T therapy in solid tumors: IL-15-autocrine signaling augments tumor stroma depletion and promotes a TSCM subset in the TME. Cell Death & Disease. 2025.","DOI":"10.1038\/s41419-025-08405-2"},{"key":"4384_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01509-2","author":"JP Murad","year":"2025","unstructured":"Murad JP, Christian L, Rosa R, Ren Y, Buckley AJ, Lee EHJ, Lopez LS, Park AK, Yang J, Yamaguchi Y (2025) Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nat Biomed Eng. https:\/\/doi.org\/10.1038\/s41551-025-01509-2","journal-title":"Nat Biomed Eng."},{"issue":"11","key":"4384_CR85","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski M, Abken H (2017) CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep 21(11):3205\u20133219","journal-title":"Cell Rep"},{"issue":"7","key":"4384_CR86","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH (2018) Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep 23(7):2130\u20132141","journal-title":"Cell Rep"},{"issue":"1","key":"4384_CR87","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, Weng J, Du X, Wu K, Lai P (2024) Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol 17(1):105","journal-title":"J Hematol Oncol"},{"issue":"10","key":"4384_CR88","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","volume":"27","author":"S Cordoba","year":"2021","unstructured":"Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, Vora A, Bonney D, Veys P, Rao K (2021) CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med 27(10):1797\u20131805","journal-title":"Nat Med"},{"key":"4384_CR89","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","volume":"11","author":"H Qin","year":"2018","unstructured":"Qin H, Ramakrishna S, Nguyen S, Fountaine TJ, Ponduri A, Stetler-Stevenson M, Yuan CM, Haso W, Shern JF, Shah NN (2018) Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther Oncolytics 11:127\u2013137","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"4384_CR90","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, Nabavizadeh A, Jarocha D, Martins R, Maloney E (2024) Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med 30(5):1320\u20131329","journal-title":"Nat Med"},{"issue":"23","key":"4384_CR91","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.23.02019","volume":"42","author":"FY Lin","year":"2024","unstructured":"Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A (2024) Phase I trial of GD2. CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors. J Clin Oncol 42(23):2769\u20132779","journal-title":"J Clin Oncol"},{"issue":"9","key":"4384_CR92","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.3390\/biomedicines10092216","volume":"10","author":"N Deshet-Unger","year":"2022","unstructured":"Deshet-Unger N, Horn G, Rawet-Slobodkin M, Waks T, Laskov I, Michaan N, Raz Y, Bar V, Zundelevich A, Aharon S (2022) Comparing intraperitoneal and intravenous personalized ErbB2CAR-T for the treatment of epithelial ovarian cancer. Biomedicines 10(9):2216","journal-title":"Biomedicines"},{"issue":"1","key":"4384_CR93","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","volume":"14","author":"N Pang","year":"2021","unstructured":"Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, Huang Y, Wu Q, Li X, He B (2021) IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol 14(1):118","journal-title":"J Hematol Oncol"},{"key":"4384_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01075-1","author":"J Li","year":"2025","unstructured":"Li J, Liu C, Zhang P, Shen L, Qi C (2025) Optimizing CAR T cell therapy for solid tumours: a clinical perspective. Nat Rev Clin Oncol. https:\/\/doi.org\/10.1038\/s41571-025-01075-1","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4384_CR95","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41392-023-01636-9","volume":"8","author":"Y Que","year":"2023","unstructured":"Que Y, Wang J, Sun F, Wang S, Zhu J, Huang J, Zhao Z, Zhang L, Liu J, Xu J (2023) Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study. Signal Transduct Target Ther 8(1):392","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4384_CR96","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ (2020) Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 21(4):541\u2013550","journal-title":"Lancet Oncol."},{"key":"4384_CR97","doi-asserted-by":"crossref","first-page":"1176790","DOI":"10.3389\/fonc.2023.1176790","volume":"13","author":"I Bertacca","year":"2023","unstructured":"Bertacca I, Pegoraro F, Tondo A, Favre C (2023) Targeted treatment of solid tumors in pediatric precision oncology. Front oncol. 13:1176790","journal-title":"Front oncol."},{"issue":"7","key":"4384_CR98","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28338","volume":"67","author":"RR Patel","year":"2020","unstructured":"Patel RR, Ramkissoon SH, Ross J, Weintraub L (2020) Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors. Pediatr Blood Cancer. 67(7):e28338","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"4384_CR99","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s43856-023-00243-7","volume":"3","author":"SA Tomlins","year":"2023","unstructured":"Tomlins SA, Khazanov NA, Bulen BJ, Hovelson DH, Shreve MJ, Lamb LE, Matrana MR, Burkard ME, Yang ES-H, Edenfield WJ (2023) Development and validation of an integrative pan-solid tumor predictor of PD-1\/PD-L1 blockade benefit. Commun med 3(1):14","journal-title":"Commun med"},{"key":"4384_CR100","first-page":"2138","volume-title":"Immunotherapy in Localized Microsatellite Instability\u2013High\/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care?","author":"KK Ciombor","year":"2023","unstructured":"Ciombor KK, Eng C (2023) Immunotherapy in Localized Microsatellite Instability\u2013High\/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care? Wolters Kluwer Health, pp 2138\u20132140"},{"issue":"15","key":"4384_CR101","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","volume":"377","author":"S Lemery","year":"2017","unstructured":"Lemery S, Keegan P, Pazdur R (2017) First FDA approval agnostic of cancer site\u2014when a biomarker defines the indication. New Engl J Med. 377(15):1409\u20131412","journal-title":"New Engl J Med."},{"issue":"7","key":"4384_CR102","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.7150\/ijbs.71714","volume":"18","author":"Y He","year":"2022","unstructured":"He Y, Zhang L, Zhou R, Wang Y, Chen H (2022) The role of DNA mismatch repair in immunotherapy of human cancer. Int J Biol Sci. 18(7):2821","journal-title":"Int J Biol Sci."},{"issue":"23","key":"4384_CR103","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1158\/1078-0432.CCR-22-2164","volume":"28","author":"KL Davis","year":"2022","unstructured":"Davis KL, Fox E, Isikwei E, Reid JM, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL (2022) A phase I\/II trial of nivolumab plus ipilimumab in children and young adults with relapsed\/refractory solid tumors: a Children\u2019s Oncology Group Study ADVL1412. Clin Cancer Res. 28(23):5088\u20135097","journal-title":"Clin Cancer Res."},{"key":"4384_CR104","doi-asserted-by":"crossref","unstructured":"Long AH, Morgenstern DA, Leruste A, Bourdeaut F, Davis KL. Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. American Society of Clinical Oncology Educational book. American Society of Clinical Oncology. Annual Meeting; 2022. 1-14 p. (vol. 42).","DOI":"10.1200\/EDBK_349799"},{"issue":"8","key":"4384_CR105","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3390\/ph17080991","volume":"17","author":"T-H Jaing","year":"2024","unstructured":"Jaing T-H, Wang Y-L, Chiu C-C (2024) Immune checkpoint inhibitors for pediatric cancers: is it still a stalemate? Pharmaceuticals. 17(8):991","journal-title":"Pharmaceuticals."},{"key":"4384_CR106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113525","volume":"198","author":"N Andr\u00e9","year":"2024","unstructured":"Andr\u00e9 N, Le Deley MC, L\u00e9guillette C, Probst A, Willems L, Travers R, Aerts I, Faure-Conter C, Revond-Riviere G, Min V (2024) METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing\/refractory solid tumors. Eur J Cancer. 198:113525","journal-title":"Eur J Cancer."},{"issue":"8","key":"4384_CR107","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","volume":"7","author":"E Pasquier","year":"2010","unstructured":"Pasquier E, Kavallaris M, Andr\u00e9 N (2010) Metronomic chemotherapy: new rationale for new directions. Nat rev Clin oncol. 7(8):455\u2013465","journal-title":"Nat rev Clin oncol."},{"key":"4384_CR108","doi-asserted-by":"crossref","first-page":"1202169","DOI":"10.3389\/fimmu.2023.1202169","volume":"14","author":"EP Vonderhaar","year":"2023","unstructured":"Vonderhaar EP, Dwinell MB, Craig BT (2023) Targeted immune activation in pediatric solid tumors: opportunities to complement local control approaches. Front Immunol. 14:1202169","journal-title":"Front Immunol."},{"key":"4384_CR109","volume":"11","author":"B Qiu","year":"2021","unstructured":"Qiu B, Kline C, Mueller S (2021) Radiation in combination with targeted agents and immunotherapies for pediatric central nervous system tumors-progress, opportunities, and challenges. Front Oncol 11:674596","journal-title":"Front Oncol"},{"key":"4384_CR110","volume":"16","author":"C Cheng","year":"2025","unstructured":"Cheng C, Wang Q, Zhang S (2025) Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms. Front Immunol 16:1610858","journal-title":"Front Immunol"},{"issue":"1","key":"4384_CR111","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10238-025-01691-2","volume":"25","author":"S Rivera-Orellana","year":"2025","unstructured":"Rivera-Orellana S, Bautista J, Palacios-Zavala D, Ojeda-Mosquera S, Altamirano-Colina A, Alcocer-Veintimilla M, Parrales-Rosales G, Izquierdo-Condoy JS, V\u00e1sconez-Gonz\u00e1lez J, Ortiz-Prado E (2025) Oncolytic virotherapy and tumor microenvironment modulation. Clin Exp Med 25(1):256","journal-title":"Clin Exp Med"},{"issue":"8062","key":"4384_CR112","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","volume":"641","author":"Y Shen","year":"2025","unstructured":"Shen Y, Bai X, Zhang Q, Liang X, Jin X, Zhao Z, Song W, Tan Q, Zhao R, Jia W (2025) Oncolytic virus VG161 in refractory Hepatocellular Carcinoma. Nature 641(8062):503\u2013511","journal-title":"Nature"},{"issue":"16","key":"4384_CR113","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/s41388-025-03357-5","volume":"44","author":"B Schoeps","year":"2025","unstructured":"Schoeps B, Lauer UM, Elbers K (2025) Deciphering permissivity of human tumor ecosystems to oncolytic viruses. Oncogene 44(16):1069\u20131077","journal-title":"Oncogene"},{"issue":"2","key":"4384_CR114","volume":"9","author":"L Yi","year":"2024","unstructured":"Yi L, Ning Z, Xu L, Shen Y, Zhu X, Yu W, Xie J, Meng Z (2024) The combination treatment of oncolytic adenovirus H101 with Nivolumab for refractory advanced Hepatocellular Carcinoma: An open-label, single-arm, pilot study. ESMO Open 9(2):102239","journal-title":"ESMO Open"},{"issue":"3","key":"4384_CR115","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/jcm12031098","volume":"12","author":"T Zhang","year":"2023","unstructured":"Zhang T, Jou TH-T, Hsin J, Wang Z, Huang K, Ye J, Yin H, Xing Y (2023) Talimogene laherparepvec (T-VEC): a review of the recent advances in cancer therapy. J clin med 12(3):1098","journal-title":"J clin med"},{"key":"4384_CR116","doi-asserted-by":"crossref","unstructured":"Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science translational medicine. 2014;6(226):226ra32-226ra32.","DOI":"10.1126\/scitranslmed.3008095"},{"key":"4384_CR117","volume":"15","author":"H Park","year":"2024","unstructured":"Park H, Kim G, Kim N, Ha S, Yim H (2024) Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Front Immunol 15:1454427","journal-title":"Front Immunol"},{"key":"4384_CR118","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1574742","volume":"16","author":"S Balkhi","year":"2025","unstructured":"Balkhi S, Zuccolotto G, Di Spirito A, Rosato A, Mortara L (2025) CAR-NK cell therapy: promise and challenges in solid tumors. Front Immunol 16:1574742","journal-title":"Front Immunol"},{"issue":"6","key":"4384_CR119","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, Rezvani K (2025) Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat med 31(6):1987\u20131993","journal-title":"Nat med"},{"key":"4384_CR120","doi-asserted-by":"crossref","unstructured":"Lin H, Case R, Wei KY, Eres I, Alba BM, Kaner J, Wu Y-C, Yamawaki TM, Mostafavi M, Zhou H. (2025) Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses. Cell Reports Medicine. 6(5).","DOI":"10.1016\/j.xcrm.2025.102117"},{"key":"4384_CR121","doi-asserted-by":"crossref","unstructured":"Fan Y, Duan Y, Chen J, Wang Y, Shang K, Jiang J, Su L, Zhou C, Sadelain M, Huang H. (2025) Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses. Nature Biomedical Engineering.1-14.","DOI":"10.1038\/s41551-025-01450-4"},{"issue":"1","key":"4384_CR122","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43556-024-00241-8","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei W, Zhou K, Lei Y, Li Q, Zhu H (2025) Cancer vaccines: platforms and current progress. Mol Biomed 6(1):3","journal-title":"Mol Biomed"},{"issue":"10427","key":"4384_CR123","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ (2024) Individualised neoantigen therapy mRNA-4157 (V940) plus Pembrolizumab versus Pembrolizumab monotherapy in resected Melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403(10427):632\u2013644","journal-title":"Lancet"},{"key":"4384_CR124","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1571182","volume":"16","author":"K Oyama","year":"2025","unstructured":"Oyama K, Nakata K, Abe T, Hirotaka K, Fujimori N, Kiyotani K, Iwamoto C, Ikenaga N, Morisaki S, Umebayashi M (2025) Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Front Immunol 16:1571182","journal-title":"Front Immunol"},{"issue":"1","key":"4384_CR125","volume":"18","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Wei Y, Tian X, Wei X (2025) Cancer vaccines: current status and future directions. J Hematol Oncol 18(1):18","journal-title":"J Hematol Oncol"},{"issue":"8","key":"4384_CR126","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.21873\/anticanres.15213","volume":"41","author":"T Morisaki","year":"2021","unstructured":"Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji K, Takeuchi A, Nakagawa S (2021) Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients with advanced solid tumors: A retrospective analysis. Anticancer Res 41(8):4101\u20134115","journal-title":"Anticancer Res"},{"key":"4384_CR127","doi-asserted-by":"crossref","unstructured":"Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A. (2025) SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 1-10.","DOI":"10.1016\/j.ijrobp.2025.06.2573"},{"issue":"1","key":"4384_CR128","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li Y, Chen K, Qian L, Wang P (2021) Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell Int 21(1):262","journal-title":"Cancer Cell Int"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04384-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04384-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:46:58Z","timestamp":1776257218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04384-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":128,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4384"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04384-1","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Patient consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"146"}}